These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 19347726)

  • 1. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
    Engert A; Griskevicius L; Zyuzgin Y; Lubenau H; del Giglio A
    Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.
    Gatzemeier U; Ciuleanu T; Dediu M; Ganea-Motan E; Lubenau H; Del Giglio A
    J Thorac Oncol; 2009 Jun; 4(6):736-40. PubMed ID: 19404210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.
    del Giglio A; Eniu A; Ganea-Motan D; Topuzov E; Lubenau H
    BMC Cancer; 2008 Nov; 8():332. PubMed ID: 19014494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
    Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
    J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
    Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.
    Scott SD; Chrischilles EA; Link BK; Delgado DJ; Fridman M; Stolshek BS
    J Manag Care Pharm; 2003; 9(2 Suppl):15-21. PubMed ID: 14613340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
    Sagara Y; Sato K; Fukuma E; Higaki K; Mizutani M; Osaki A; Takano T; Tokuda Y; Ohno S; Masuda N; Suzuki M; Saeki T
    Jpn J Clin Oncol; 2013 Sep; 43(9):865-73. PubMed ID: 23858037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
    Lane SW; Crawford J; Kenealy M; Cull G; Seymour JF; Prince HM; Marlton P; Gill D; Mollee PN
    Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
    Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
    Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Semiglazov V; Krasnozhon D; Davidenko I; Nelyubina L; Nakov R; Stiegler G; Singh P; Schwebig A; Kramer S; Harbeck N
    Ann Oncol; 2015 Sep; 26(9):1948-1953. PubMed ID: 26122726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.
    Lee S; Knox A; Zeng IS; Coomarasamy C; Blacklock H; Issa S
    Support Care Cancer; 2013 Mar; 21(3):841-6. PubMed ID: 22972488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    Wang L; Baser O; Kutikova L; Page JH; Barron R
    Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
    Gisselbrecht C; Haioun C; Lepage E; Bastion Y; Tilly H; Bosly A; Dupriez B; Marit G; Herbrecht R; Deconinck E; Marolleau JP; Yver A; Dabouz-Harrouche F; Coiffier B; Reyes F
    Leuk Lymphoma; 1997 Apr; 25(3-4):289-300. PubMed ID: 9168439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
    Almenar D; Mayans J; Juan O; Bueno JM; Lopez JI; Frau A; Guinot M; Cerezuela P; Buscalla EG; Gasquet JA; Sanchez J
    Eur J Cancer Care (Engl); 2009 May; 18(3):280-6. PubMed ID: 19076208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
    J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.